Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

ConferencePositive

AI Analysis

Summary

Telix Pharmaceuticals will present 20 abstracts at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) highlighting pivotal trials in prostate, brain, and renal cancers, as well as next generation theranostics.

Importance:5/10

Sentiment:

0.30

theranosticsoncologyconferenceEANMpivotal trials

Related Companies

$TLX

Read the original article

Published by PR Newswire Biotech on October 14, 2026 5:00 AM

Read Original